The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to measure the effect that various doses of LY2409021 have on blood sugar levels and on the amount of glucose released by the liver, when glucagon is given to increase these. Each participant may receive up to 2 single doses of LY2409021 in 2 different study periods, with a minimum 13-day washout between dosing periods. This study is approximately 9 weeks long, not including screening. A screening appointment is required within 6 weeks prior to the start of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

NCT01986231

Type 1 Diabetes Mellitus

COMPLETED NA

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

NCT05887999

Diabetes Mellitus, Type 1

COMPLETED PHASE1

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

NCT02792400

Type 2 Diabetes

COMPLETED NA

Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

NCT02016846

Glucocorticoid Induced Hyperglycemia

UNKNOWN PHASE3

Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

NCT01300260

Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

* Are allergic to LY2409021, insulin, glucagon, somatostatin, or similar drugs
* Have a regular alcohol intake greater than 21 units/week, or are unwilling to stop alcohol as required by the study restrictions (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits)
* Are currently smokers or have used tobacco products on a regular basis in the 6 months prior to screening
* Have received any medication known to affect glucose metabolism in the 1 month before the study
* Have a significant blood disorder and/or donated blood (450 mL or more) in the last 3 months

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes